---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122771"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:10:47.059695+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Geron posts Q3 RYTELO revenue of $28.2M; secures up to $375M in financing

## Summary
- Net product revenue of $28.2M from RYTELO in first full quarter of U.S. launch.
- Net loss of $26.4M ($0.04 per share) vs. $44.8M loss in Q3 2023.
- Total operating expenses guidance for FY2024 set at $260M–$270M.
- Received $250M gross proceeds: $125M from Royalty Pharma, $125M from Pharmakon loan.
- Additional $125M debt available; $86.5M Hercules loan repaid and terminated.

## SEC filing metadata
- accession: 0000950170-24-122771
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 2.02, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017024122771/0000950170-24-122771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017024122771/gern-20241101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122771
- JSON: https://secwatch.observer/filing/0000950170-24-122771.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.